Format

Send to

Choose Destination
Blood. 2017 Oct 12;130(15):1706-1712. doi: 10.1182/blood-2017-05-782060. Epub 2017 Aug 23.

Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study.

Author information

1
Department of Medicine and.
2
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
3
Coagulation Unit, Hematology Center, Karolinska University Hospital, Stockholm, Sweden.
4
Central Clinical School, Monash University and Alfred Hospital, Melbourne, Australia.
5
Department of Molecular Medicine and Surgery and.
6
Clinical Chemistry and Blood Coagulation Research, Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
7
Science for Life Laboratory, School of Biotechnology, Royal Institute of Technology, Stockholm, Sweden.
8
Division of Pediatrics, Department of Clinical Science Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
9
Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden.
10
Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
11
Department of Medicine, McMaster University, Hamilton, ON, Canada; and.
12
Thrombosis and Atherosclerosis Research Institute, Hamilton, ON, Canada.

Abstract

There is uncertainty regarding the effectiveness and occurrence of thromboembolic events in patients treated with prothrombin complex concentrates (PCCs) for the management of major bleeding events (MBEs) on rivaroxaban or apixaban. We investigated the effectiveness of PCCs given for the management of MBEs in patients on rivaroxaban or apixaban. Between 1 January 2014 and 1 October 2016, we prospectively included patients on rivaroxaban or apixaban treated with PCCs for the management of MBEs. The effectiveness of PCCs was assessed by using the International Society of Thrombosis and Hemostasis Scientific and Standardization Subcommittee criteria for the assessment of the effectiveness of major bleeding management. The safety outcomes were thromboembolic events and all-cause mortality within 30 days after treatment with PCCs. A total of 84 patients received PCCs for the reversal of rivaroxaban or apixaban due to a MBE. PCCs were given at a median (interquartile range) dose of 2000 IU (1500-2000 IU). Intracranial hemorrhage (ICH) was the most common site of bleeding requiring reversal (n = 59; 70.2%), followed by gastrointestinal bleeding in 13 (15.5%) patients. Management with PCCs was assessed as effective in 58 (69.1%) patients and ineffective in 26 (30.9%) patients. Most patients with ineffective hemostasis with PCCs had ICH (n = 16; 61.5%). Two patients developed an ischemic stroke, occurring 5 and 10 days after treatment with PCC. Twenty-seven (32%) patients died within 30 days after a MBE. The administration of PCCs for the management of MBEs associated with rivaroxaban or apixaban is effective in most cases and is associated with a low risk of thromboembolism. Our findings are limited by the absence of a control group in the study.

PMID:
28835439
DOI:
10.1182/blood-2017-05-782060
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center